- Home
- IMNN vs TRIB Comparison
IMNN vs TRIB Comparison
Compare IMNN & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- TRIB
- Stock Information
- Founded
- IMNN 1982
- TRIB 1992
- Country
- IMNN United States
- TRIB Ireland
- Employees
- IMNN N/A
- TRIB N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IMNN Health Care
- TRIB Health Care
- Exchange
- IMNN Nasdaq
- TRIB Nasdaq
- Market Cap
- IMNN 12.1M
- TRIB 13.0M
- IPO Year
- IMNN 1985
- TRIB N/A
- Fundamental
- Price
- IMNN $0.77
- TRIB $0.65
- Analyst Decision
- IMNN Buy
- TRIB
- Analyst Count
- IMNN 2
- TRIB 0
- Target Price
- IMNN $14.00
- TRIB N/A
- AVG Volume (30 Days)
- IMNN 5.4M
- TRIB 2.4M
- Earning Date
- IMNN 08-13-2025
- TRIB 08-13-2025
- Dividend Yield
- IMNN N/A
- TRIB N/A
- EPS Growth
- IMNN N/A
- TRIB N/A
- EPS
- IMNN N/A
- TRIB N/A
- Revenue
- IMNN N/A
- TRIB $61,555,000.00
- Revenue This Year
- IMNN N/A
- TRIB $13.51
- Revenue Next Year
- IMNN N/A
- TRIB $13.14
- P/E Ratio
- IMNN N/A
- TRIB N/A
- Revenue Growth
- IMNN N/A
- TRIB 8.31
- 52 Week Low
- IMNN $0.37
- TRIB $0.48
- 52 Week High
- IMNN $3.65
- TRIB $3.44
- Technical
- Relative Strength Index (RSI)
- IMNN 40.14
- TRIB 48.68
- Support Level
- IMNN $0.93
- TRIB $0.60
- Resistance Level
- IMNN $1.03
- TRIB $0.87
- Average True Range (ATR)
- IMNN 0.18
- TRIB 0.08
- MACD
- IMNN -0.10
- TRIB 0.01
- Stochastic Oscillator
- IMNN 1.39
- TRIB 33.94
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.